Sequencing, Safety, and Clinical Decision-Making With HER2-Targeted Therapies in GEA

This program was supported by Jazz Pharmaceuticals, with content independence maintained by Pharmacy Times.

In this part of the discussion, Matthew Arango, PharmD, reviews what the DESTINY-Gastric studies have shown about trastuzumab deruxtecan (Enhertu; Daiichi Sankyo, AstraZeneca) in patients with progressive HER2-positive gastroesophageal adenocarcinoma (GEA), including response rates, survival benefits, and important safety considerations such as interstitial lung disease. He explains how these data inform therapy sequencing, particularly the rationale for moving from a first-line bispecific antibody like zanidatamab to an antibody-drug conjugate in the second-line setting.